MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjopen-2015-007651

Медицинская библиотека · BMJ open · 2015

Randomised controlled trial of topical kanuka honey for the treatment of rosacea.

Braithwaite Irene, Hunt Anna, Riley Judith, Fingleton James, Kocks Janwillem, Corin Andrew, Helm Colin, Sheahan Davitt, Tofield Christopher, Montgomery Barney, Holliday Mark, Weatherall Mark, Beasley Richard

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea.

DESIGN

Randomised controlled trial with blinded assessment of primary outcome variable.

SETTING

Outpatient primary healthcare population from 5 New Zealand sites.

PARTICIPANTS

138 adults aged ≥ 16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ≥ 2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively.

INTERVENTIONS: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8 weeks.

MAIN OUTCOME MEASURES: The primary outcome measure was the proportion of participants who had a ≥ 2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100 mm scale (0 mm 'much worse', 100 mm 'much improved') at weeks 2 and 8.

RESULTS

24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ≥ 2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was -1 (Hodges-Lehman estimate, 95% CI -1 to 0, p=0.03), and at week 8 minus baseline was -1 (Hodges-Lehman estimate, 95% CI -1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control.

CONCLUSIONS

Honevo is an effective treatment for rosacea.

TRIAL REGISTRATION NUMBER: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.

Для цитирования: Braithwaite Irene, Hunt Anna, Riley Judith, Fingleton James, Kocks Janwillem, Corin Andrew, Helm Colin, Sheahan Davitt, Tofield Christopher, Montgomery Barney, Holliday Mark, Weatherall Mark, Beasley Richard. Randomised controlled trial of topical kanuka honey for the treatment of rosacea.. BMJ open. 2015. DOI: 10.1136/bmjopen-2015-007651.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.